HC Wainwright Comments on Urogen Pharma Q3 Earnings

Urogen Pharma (NASDAQ:URGN) – Stock analysts at HC Wainwright issued their Q3 2027 earnings estimates for shares of Urogen Pharma in a report issued on Thursday, April 23rd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of $0.27 for the quarter. The consensus estimate for Urogen Pharma’s current full-year earnings is ($1.20) per share.

A number of other research analysts have also recently issued reports on URGN. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Monday, March 2nd. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research note on Tuesday, March 31st. Jefferies Financial Group initiated coverage on shares of Urogen Pharma in a research note on Friday, April 10th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and an average price target of $34.13.

Urogen Pharma Price Performance

NASDAQ URGN opened at $24.31 on Friday. The stock’s 50 day simple moving average is $20.03 and its 200 day simple moving average is $21.08. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00. The firm has a market cap of $1.18 billion, a PE ratio of -7.60 and a beta of 1.43.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.12. The firm had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million.

Insider Activity

In other Urogen Pharma news, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the transaction, the insider directly owned 144,985 shares in the company, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the sale, the general counsel owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently bought and sold shares of the company. Osaic Holdings Inc. raised its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after purchasing an additional 486 shares in the last quarter. State of Wyoming acquired a new position in shares of Urogen Pharma during the 3rd quarter worth approximately $66,000. Russell Investments Group Ltd. raised its stake in shares of Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of Urogen Pharma in the third quarter valued at $76,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.